WO2023020521 - PYRIDINE FUSED PYRIMIDINE DERIVATIVES AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2023/020521
Publication Date
23.02.2023
International Application No.
PCT/CN2022/112927
International Filing Date
17.08.2022
Title **
[English]
PYRIDINE FUSED PYRIMIDINE DERIVATIVES AND USE THEREOF
[French]
DÉRIVÉS DE PYRIMIDINE FUSIONNÉE AVEC LA PYRIDINE ET LEUR UTILISATION
Applicants **
JACOBIO PHARMACEUTICALS CO., LTD.
Unit 2
Building 5, BYBP, No. 88 Kechuang Street 6th
Business Development Area Daxing
Beijing 101111, CN
Inventors
YANG, Hongwei
Unit 2
Building 5, BYBP, No. 88 Kechuang Street 6th
Business Development Area Daxing
Beijing 101111, CN
MA, Cunbo
Unit 2
Building 5, BYBP, No. 88 Kechuang Street 6th
Business Development Area Daxing
Beijing 101111, CN
GAO, Panliang
Unit 2
Building 5, BYBP, No. 88 Kechuang Street 6th
Business Development Area Daxing
Beijing 101111, CN
HAN, Huifeng
Unit 2
Building 5, BYBP, No. 88 Kechuang Street 6th
Business Development Area Daxing
Beijing 101111, CN
WANG, Peng
Unit 2
Building 5, BYBP, No. 88 Kechuang Street 6th
Business Development Area Daxing
Beijing 101111, CN
LI, Runze
Unit 2
Building 5, BYBP, No. 88 Kechuang Street 6th
Business Development Area Daxing
Beijing 101111, CN
LIU, Xiaoyu
Unit 2
Building 5, BYBP, No. 88 Kechuang Street 6th
Business Development Area Daxing
Beijing 101111, CN
WANG, Yanping
Unit 2
Building 5, BYBP, No. 88 Kechuang Street 6th
Business Development Area Daxing
Beijing 101111, CN
LONG, Wei
Unit 2
Building 5, BYBP, No. 88 Kechuang Street 6th
Business Development Area Daxing
Beijing 101111, CN
ZHANG, Wei
Unit 2
Building 5, BYBP, No. 88 Kechuang Street 6th
Business Development Area Daxing
Beijing 101111, CN
Priority Data
PCT/CN2021/113365
18.08.2021
CN
PCT/CN2021/123604
13.10.2021
CN
PCT/CN2021/124118
15.10.2021
CN
PCT/CN2021/132066
22.11.2021
CN
PCT/CN2021/132636
24.11.2021
CN
PCT/CN2022/074165
27.01.2022
CN
PCT/CN2022/087377
18.04.2022
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2856 | |
| EPO | Filing, Examination | 18629 | |
| Japan | Filing | 595 | |
| South Korea | Filing | 770 | |
| USA | Filing, Examination | 10560 |
Total: 33410 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention relates to a compound of Formula (I), stereoisomer thereof, pharmaceutically acceptable salt thereof, pharmaceutically acceptable salt of the stereoisomer thereof, prodrug thereof, deuterated molecule thereof or conjugated form thereof; composition containing the same and the use thereof.[French]
L'invention concerne un composé de formule (I), un stéréoisomère de celui-ci, un sel pharmaceutiquement acceptable de celui-ci, un sel pharmaceutiquement acceptable du stéréoisomère de celui-ci, un promédicament de celui-ci, une molécule deutérée de celui-ci ou une forme conjuguée de celui-ci; une composition le contenant et son utilisation.